StreetInsider.com News Articles

Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS)

Wed, 20 May 2026 09:37:17 -0400

Benchmark analyst Robert Wasserman reiterated a Speculative Buy rating and $12.00 price target on Intensity Therapeutics, Inc. (NASDAQ: INTS).

The analyst commented, "Intensity Therapeutics reported financial results for their 1Q26 and provided an update on their clinical progress. Highlights during the first quarter included approval by the Swissmedic federal agency to resume enrollment in the Invincible4 study with INT230-6 in triple negative breast cancer (TNBC) following favorable efficacy and safety reported in a small patient sample size (5 out of 7), and a decision by the Company to resume enrollment in a limited number of US sites for the Invincible3 study

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thu, 14 May 2026 08:00:00 -0400

Company receives the Cancer Treatment Technology Innovator of the Year award

SHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Cancer Treatment Technology Innovator of the Year

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thu, 14 May 2026 08:00:00 -0400

Company receives the Cancer Treatment Technology Innovator of the Year award

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thu, 14 May 2026 08:00:00 -0400

Company receives the Cancer Treatment Technology Innovator of the Year award

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Thu, 14 May 2026 08:00:00 -0400

Company receives the Cancer Treatment Technology Innovator of the Year award

Intensity Therapeutics, Inc. (INTS) Misses Q1 EPS by 90c

Thu, 07 May 2026 16:47:36 -0400

Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q1 EPS of ($0.96), $0.90 worse than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.

Form 8-K INTENSITY THERAPEUTICS, For: May 07

Thu, 07 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26453267.html

Form 8-K INTENSITY THERAPEUTICS, For: May 07

Thu, 07 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26453267.html

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Thu, 07 May 2026 16:06:00 -0400

Cash and cash equivalents of $10.2 million as of March 31, 2026

Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)

Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026

Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026

SHELTON,

Form 10-Q INTENSITY THERAPEUTICS, For: Mar 31

Thu, 07 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260507/26452639.html

Form 10-Q INTENSITY THERAPEUTICS, For: Mar 31

Thu, 07 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260507/26452639.html

Form ARS INTENSITY THERAPEUTICS, For: Dec 31

Thu, 30 Apr 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260430/26407925.html

Form ARS INTENSITY THERAPEUTICS, For: Dec 31

Thu, 30 Apr 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260430/26407925.html

Form DEFA14A INTENSITY THERAPEUTICS,

Thu, 30 Apr 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260430/26407902.html

Form DEFA14A INTENSITY THERAPEUTICS,

Thu, 30 Apr 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260430/26407902.html

Form DEF 14A INTENSITY THERAPEUTICS, For: Apr 30

Thu, 30 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260430/26407756.html

Form DEF 14A INTENSITY THERAPEUTICS, For: Apr 30

Thu, 30 Apr 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260430/26407756.html

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

Wed, 15 Apr 2026 09:15:00 -0400

Company receives the Platinum Award for Innovator in Biotech Solutions Category

SHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug